The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 05 Sep 2017 Planned number of patients changed from 376 to 348.
- 19 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Jan 2020 as reported by ClinicalTrials.gov
- 19 Aug 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2019 as reported by ClinicalTrials.gov